Logo

Hetero's Tocira (biosimilar- tocilizumab) Receives the DCGI's EUA for the Treatment of COVID-19 in Hospitalized Adults

Share this
Hetero's Tocira (biosimilar- tocilizumab) Receives the DCGI's EUA for the Treatment of COVID-19 in Hospitalized Adults

Hetero's Tocira (biosimilar- tocilizumab) Receives the DCGI's EUA for the Treatment of COVID-19 in Hospitalized Adults

Shots:

  • DCGI has granted a EUA for tocilizumab in India for the treatment of COVID-19 in hospitalized adults who receives systemic corticosteroids and require supplemental oxygen- non-invasive or invasive mechanical ventilation- or ECMO
  • Hetero’s Tocira will be marketed by Hetero Healthcare in India & manufactured by Hetero Biologics
  • Tocilizumab (400mg/20ml) is the biosimilar referencing Roche’s Actemra/RoActemra and is expected to be available at the end of Sept’21

| Ref: Hetero | Image: Pharma Boardroom

Click here to­ read the full press release 

Tuba

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions